Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Shenzhen Hepalink Forms $9 Million Cancer JV with Canada's Quest PharmaTech

publication date: Mar 22, 2016

Shenzhen Hepalink Pharma has deepened its relationship with Canada's Quest PharmaTech. The two companies will form a $9 million China JV to fund R&D of Quest's cancer immunotherapies in China. Hepalink will invest $5 million for a 54% stake in the JV. OncoQuest, the oncology subsidiary of Quest, will contribute China rights to its immunotherapy technologies along with $1 million in cash for the remaining 46%. The partners put a value of $9.26 million on the JV. In 2015, Hepalink paid $13 million for a 42% stake in OncoQuest. More details....

Stock Symbols: (SHZ: 002399) (TSX-V: QPT)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital